Last updated 2026-07-27
TL;DR
Topical dapsone gel (Aczone) reduced inflammatory acne lesions by roughly 30-48% over 12 weeks in FDA trials, mostly cosmetic and slow. Oral dapsone is a different drug entirely, a sulfone antibiotic that can cause hemolysis and dangerous blood reactions in people with G6PD deficiency, and it is not an approved or sensible acne treatment for casual use.
What do "before and after" claims for dapsone actually mean?
When people search for dapsone before and after photos, they're almost always talking about topical dapsone gel, sold under the brand name Aczone, used for acne. The claim behind those photos is usually some version of "clearer skin in 8 to 12 weeks," fewer red bumps, less oil, calmer skin overall. That claim has real trial data behind it, which puts topical dapsone ahead of a lot of skincare marketing. The original FDA approval studies for Aczone 5% gel, published in the Journal of Drugs in Dermatology, found that patients using the gel twice daily for 12 weeks had significantly greater reductions in inflammatory lesion counts than those on vehicle gel alone [1]. The newer 7.5% once-daily formulation showed similar results in two phase 3 trials submitted to the FDA, with roughly a 48% reduction in inflammatory lesions at week 12 in one of the key studies, compared to about 43% with vehicle [2]. Notice those numbers are close. That's the honest part nobody puts in a before-and-after caption: dapsone gel beats placebo, but not by a landslide. It's a moderate acne treatment, not a dramatic one. If someone shows you a jaw-dropping transformation photo attributed to dapsone gel alone, be skeptical. Most real-world "after" photos involve combination routines: dapsone plus a retinoid, dapsone plus benzoyl peroxide, or dapsone as one piece of a broader acne regimen a dermatologist built. For background on the drug's actual FDA-approved use and how it works on skin, see what does Dapsone Rx actually do.
How long does topical dapsone take to work for acne?
Most people should not expect to see a real difference before week 4, and the meaningful data points come at week 12. This is not a two-week fix. In the key trials for Aczone 7.5% gel, investigators measured inflammatory and noninflammatory lesion counts at multiple checkpoints, and separation from vehicle gel became statistically significant by week 12, with some improvement visible earlier [2]. Dermatology practice guidance generally tells patients to commit to at least 8 to 12 weeks before judging whether a topical acne treatment is working, and that guidance applies here too. A few practical points worth knowing before you start: - Mild dryness, redness, or peeling in the first 2 to 4 weeks is common and usually fades.
- Applying benzoyl peroxide at the same time can cause a temporary yellow-orange skin discoloration; the trials note this interaction, and most clinicians recommend using them at different times of day [1].
- Full assessment of whether it's working really needs the 12-week mark, not week 3 or 4. If you stop at week 3 because you don't see a transformation, you're stopping before the drug had a chance to do what the trial data actually showed it can do.
What does the acne evidence actually show, in numbers?
| Aczone 5% gel, original trials | 12 weeks | ~30-39% (varies by trial) | ~19-31% [1] | |
|---|---|---|---|---|
| Aczone 7.5% gel, phase 3 trial 1 | 12 weeks | ~48.6% | ~43.2% [2] | |
| Aczone 7.5% gel, phase 3 trial 2 | 12 weeks | ~43.2% | ~39.4% [2] | Those vehicle (placebo gel) numbers are not small. A meaningful chunk of the improvement in any acne trial comes from just applying something twice a day, keeping skin clean, and the natural fluctuation of acne over 12 weeks. Dapsone gel adds a real, statistically significant edge on top of that, but it is an edge, not a cure. Where topical dapsone tends to shine most, based on subgroup data in the trials, is adult women with mild to moderate inflammatory acne, particularly along the jawline and lower face [1][2]. It has less evidence behind it for severe nodulocystic acne, where oral treatments or isotretinoin usually do more work. One quotable, source-backed fact worth remembering: the FDA-reviewed trials for Aczone 7.5% gel showed inflammatory lesion reductions in the high 40% range over 12 weeks, only a few points ahead of vehicle gel alone [2]. |
Here's the trial data stripped of marketing language. | Study/formulation | Duration | Inflammatory lesion reduction (drug) | Inflammatory lesion reduction (vehicle) |
Is topical dapsone (Aczone) the same drug as oral dapsone?
Chemically, yes. Clinically, they might as well be different medicines. Both contain dapsone, a sulfone. But the topical gel is absorbed into the bloodstream only in tiny amounts. Studies measuring systemic absorption after topical application found blood levels roughly 100 times lower than what oral dapsone produces at typical antibacterial or dermatitis-treatment doses [1]. That's the whole reason topical dapsone can be sold without routine blood monitoring or G6PD screening, while oral dapsone absolutely requires it. Oral dapsone is an FDA-approved treatment for conditions like dermatitis herpetiformis and leprosy (Hansen's disease), and it's sometimes prescribed off-label for other inflammatory skin conditions [3]. It is not an approved treatment for acne. If you see oral dapsone marketed or shared online as an acne fix, that is off-label use of a systemic antibiotic-class drug with real, sometimes serious risks, not a shortcut to what the topical gel trials showed. For the regulatory distinction in plain terms, see is Dapsone Rx fda approved and Dapsone Rx legal status.
What are the real risks of oral dapsone, and why does G6PD matter?
This is the section that matters most if anyone in your life is considering oral dapsone for any reason, including acne. Oral dapsone can cause hemolytic anemia, a breakdown of red blood cells, and this risk rises sharply in people with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic enzyme condition that affects an estimated 4.9% of the global population according to a widely cited G6PD deficiency prevalence analysis [4]. Dapsone's FDA-approved prescribing information states that patients should be screened for G6PD deficiency before starting therapy, because deficient patients face a much higher risk of severe hemolysis [3]. Beyond hemolysis, oral dapsone carries several other serious risks documented in its prescribing information [3]: - Methemoglobinemia, a condition where blood loses its ability to carry oxygen effectively, causing symptoms like bluish skin, fatigue, and shortness of breath.
- Dapsone hypersensitivity syndrome, a rare but potentially life-threatening reaction that can include fever, rash, and organ involvement, typically appearing 2 to 6 weeks after starting the drug.
- Agranulocytosis, a dangerous drop in infection-fighting white blood cells, which the label flags as a rare but serious event requiring blood count monitoring. None of this means oral dapsone is a bad drug. For dermatitis herpetiformis and leprosy, it's genuinely effective and the FDA has approved it for exactly those uses [3]. But treating it as a casual acne option, without G6PD testing and physician oversight, ignores exactly the risks its own label exists to warn about. For a full risk rundown, see Dapsone Rx contraindications.
Who should not use dapsone, topical or oral?
For topical dapsone gel, the FDA label lists sensitivity to dapsone or any gel component as the main contraindication, and notes that G6PD deficiency testing is not required before starting topical treatment, unlike the oral form [1]. Still, the label mentions that some patients with G6PD deficiency have shown mild laboratory signs of hemolysis while using the topical gel, so people who already know they have G6PD deficiency should mention it to their prescriber anyway. For oral dapsone, the contraindication list is longer and more serious. Confirmed G6PD deficiency is a major caution requiring careful risk-benefit discussion, known dapsone hypersensitivity, and pre-existing severe anemia are all reasons a physician would avoid or delay starting it [3]. Pregnant or breastfeeding patients, people on certain interacting drugs (like trimethoprim, which can increase dapsone blood levels), and anyone with significant liver or kidney impairment also need individualized evaluation before oral dapsone is appropriate [3]. The bottom line for contraindications is asymmetrical, which is the whole point of separating these two drugs in your head: topical dapsone has a short, manageable list; oral dapsone has a list serious enough that it needs bloodwork and a prescriber actively managing it, not a one-time script.
How does topical dapsone compare to other acne treatments?
| Topical dapsone 7.5% gel | ~43-49% at 12 weeks [2] | 8-12 weeks | Modest edge over vehicle, mild irritation | |
|---|---|---|---|---|
| Benzoyl peroxide | Comparable range, varies by strength and study | 4-8 weeks | Bleaching of fabric, dryness | |
| Topical retinoids (adapalene, tretinoin) | Often similar or slightly higher, varies by trial | 8-12 weeks | Dryness, sun sensitivity, initial purging | |
| Oral isotretinoin | Often 80%+ clearance, most trials show near-complete remission | Months (full course) | Teratogenic, needs strict monitoring | |
| Oral antibiotics (doxycycline, etc.) | Moderate, similar range to topicals | 6-12 weeks | Resistance concerns, GI effects | Topical dapsone's real selling point isn't superior efficacy; it's tolerability. Trials found it caused less dryness and irritation than some retinoids, making it a reasonable option for people who can't tolerate tretinoin or adapalene [1]. Dermatologists often combine it with a retinoid or benzoyl peroxide rather than using it alone, because the combination targets acne through different mechanisms (dapsone is anti-inflammatory; retinoids normalize skin cell turnover; benzoyl peroxide kills acne-causing bacteria). |
Dapsone gel sits in the middle of the acne treatment lineup, not at the top and not at the bottom. | Treatment | Typical inflammatory lesion reduction | Time to effect | Key downside |
How long until dapsone gel is out of your system?
This matters more for understanding side effect timing than for daily dosing decisions. Topical dapsone's systemic absorption is low, but the small amount that does enter the bloodstream still follows a half-life, and understanding that helps explain why side effects (when they happen) tend to show up and fade within a predictable window. For a full breakdown of absorption and clearance timing, see Dapsone Rx half life. The short version: oral dapsone has a much longer, more clinically significant half-life (in the range of 20-30 hours in most reported studies) than the trace systemic exposure from topical use, which is part of why oral dosing requires monitoring that topical use does not [3].
What should you actually expect from a before-and-after with dapsone gel?
Realistically: fewer new inflammatory pimples, calmer skin tone, less redness, over roughly 12 weeks, with continued improvement if you keep using it consistently past that point. Do not expect it to erase acne scars (it doesn't address existing scarring), clear severe cystic acne on its own, or work in under a month. The FDA trial data puts the honest ceiling at around a high-40s percentage reduction in inflammatory lesions versus a high-30s to low-40s percentage reduction with vehicle gel alone [2]. That's a real, meaningful, but not dramatic difference. If you're evaluating whether a specific before-and-after photo is credible, ask what else the person was using. Combination therapy is extremely common in real-world acne treatment, and a single-ingredient transformation attributed only to dapsone gel should raise an eyebrow, since no trial has shown results anywhere near a total clear-up from the gel alone. If you're ready to move forward with topical dapsone, the sensible path is a provider review rather than guessing at concentration or frequency yourself. Dapsone Rx works through provider-reviewed channels, with prescriptions filled through a licensed pharmacy partner. Nobody should be compounding this at home, and nobody should be trying oral dapsone for acne without a full G6PD workup and a physician managing it directly.
Frequently asked questions
How fast does dapsone gel work for acne?
Most trial data shows meaningful separation from placebo gel by week 12, with some improvement visible earlier. Aczone's phase 3 trials measured lesion counts through 12 weeks; don't judge results before at least 8 weeks of consistent twice-daily (5%) or once-daily (7.5%) use [2].
Does dapsone gel really clear acne, or is it mostly marketing?
It's real but modest. FDA trial data shows roughly a 43-49% reduction in inflammatory lesions at 12 weeks versus about 39-43% with vehicle gel alone [2]. That's a genuine, statistically significant benefit, not a dramatic transformation drug.
Is oral dapsone safe to use for acne?
Oral dapsone is not FDA-approved for acne and is not a casual acne treatment. It's a sulfone antibiotic approved for dermatitis herpetiformis and leprosy, carrying risks of hemolysis, methemoglobinemia, and dapsone hypersensitivity syndrome, and it requires G6PD deficiency screening before use [3].
What is G6PD deficiency and why does it matter for dapsone?
G6PD deficiency is a genetic enzyme condition affecting an estimated 4.9% of people worldwide [4]. It raises the risk of severe hemolytic anemia when someone takes oral dapsone, which is why the FDA-approved label calls for G6PD testing before starting oral therapy [3]. This risk does not meaningfully apply to topical dapsone gel.
Can you use dapsone gel and benzoyl peroxide together?
You can, but expect temporary yellow-orange skin or facial hair discoloration if applied at the same time; this interaction is noted in the Aczone trial data [1]. Most clinicians suggest applying them at different times of day, such as dapsone in the morning and benzoyl peroxide at night, or vice versa.
How long does it take to see results from Aczone 7.5%?
Phase 3 trials measured results through 12 weeks, with inflammatory lesion reductions around 43-49% by that point [2]. Some patients notice less redness within a few weeks, but the clinically studied endpoint is 12 weeks of consistent once-daily use.
Is topical dapsone the same risk level as oral dapsone?
No. Topical dapsone gel has systemic absorption roughly 100 times lower than oral dosing, so it does not require G6PD screening or blood monitoring in most patients, unlike oral dapsone [1][3]. They share a molecule but not a risk profile.
What side effects should you expect from dapsone gel?
The most common side effects reported in trials were mild dryness, redness, oiliness at the application site, and occasional peeling, usually in the first few weeks [1]. Serious systemic side effects are rare with topical use because absorption into the bloodstream is minimal.
Can dapsone gel cause hemolytic anemia like the oral form does?
It's rare. The topical label notes that some G6PD-deficient patients showed mild laboratory evidence of hemolysis in trials, but clinically significant hemolytic anemia from topical use is uncommon compared to oral dapsone, which carries a much stronger, well-documented hemolysis risk [1][3].
Who should not use topical dapsone gel?
Anyone with a known allergy to dapsone or gel components should avoid it. People with known G6PD deficiency aren't automatically excluded but should tell their prescriber, since mild hemolysis markers have appeared in some trial patients [1].
Does dapsone gel work for cystic or severe acne?
The trial evidence focuses on mild to moderate inflammatory acne, not severe nodulocystic acne. For severe acne, oral options like isotretinoin have much higher clearance rates in trials and are generally the better-studied path [1][2].
What's the difference between Aczone 5% and 7.5% gel?
Aczone 5% is applied twice daily; Aczone 7.5% is applied once daily and was studied in later phase 3 trials showing comparable inflammatory lesion reductions (roughly 43-49% at 12 weeks) [2]. The 7.5% formulation is often preferred for convenience of once-daily dosing.
Sources
- Draelos ZD, et al. Efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris in adult females. J Drugs Dermatol. 2016. PMID: 26741393: Trial data on inflammatory lesion reduction, tolerability, and benzoyl peroxide discoloration interaction for topical dapsone 5% gel
- Eichenfield LF, et al. Once-daily dapsone gel 7.5% for treatment of acne vulgaris: phase 3 trial results. J Drugs Dermatol. 2016. PMID: 27479094: Phase 3 trial inflammatory lesion reduction percentages for Aczone 7.5% gel versus vehicle at 12 weeks
- DailyMed, Dapsone Tablets, USP, 25 mg and 100 mg, Prescribing Information: Oral dapsone approved uses, G6PD screening requirement, hemolysis, methemoglobinemia, dapsone hypersensitivity syndrome, agranulocytosis warnings, and half-life data
- Nkhoma ET, et al. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009. PMID: 19398340: Estimated global prevalence of G6PD deficiency at approximately 4.9%
- Piette WW, et al. Dapsone gel 5% versus vehicle in the treatment of acne vulgaris: results of two randomized, double-blind, placebo-controlled trials. Arch Dermatol. 2007. PMID: 17638733: Original pivotal trial design and lesion count comparisons supporting the initial FDA approval of Aczone 5% gel